**FOI Ref: 6284**

**Category(ies): Clinical - Drugs**

**Subject: Dermatological Conditions**

**Date Received: 10/03/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question.How many patients were treated in February 2022 (or latest available month) by the dermatology department with the following drugs:* Abrocitinib (Cibinqo)
* Baricitinib (Olumiant)
* Bimekizumab (Bimzelx)
* Brodalumab (Kyntheum)
* Dupilumab (Dupixent)
* Ixekizumab (Taltz)
* Risankizumab (Skyrizi)
* Guselkumab (Tremfya)
* Secukinumab (Cosentyx)
* Tildrakizumab (Ilumetri)
* Tralokinumab (Adtralza)
* Upadacitinib (Rinvoq)
* Ustekinumab (Stelara)
 |

|  |  |
| --- | --- |
| Abrocitinib (Cibinqo) | 0 |
| Baricitinib (Olumiant) | 1 |
| Bimekizumab (Bimzelx) | 0 |
| Brodalumab (Kyntheum) | 2 |
| Dupilumab (Dupixent) | 12 |
| Ixekizumab (Taltz) | 0 |
| Risankizumab (Skyrizi) | 0 |
| Guselkumab (Tremfya) | 12 |
| Secukinumab (Cosentyx) | 4 |
| Tildrakizumab (Ilumetri) | 0 |
| Tralokinumab (Adtralza) | 0 |
| Upadacitinib (Rinvoq) | 0 |
| Ustekinumab (Stelara) | 4 |

 |